Eule H, Roth I, Weinecke A, Wuthe H
Z Erkr Atmungsorgane. 1985;164(1):43-59.
Preliminary results of a prospective clinical trial to evaluate the value of corticosteroid therapy of intrathoracic sarcoidosis had demonstrated that there were no differences between treated and untreated patients with regard to the clinical, radiological and functional outcome after several years. In one hundred and seventy two patients we could check the former results by identical tests after a longer follow-up period (mean 8,9 years) and by additional physiological assessments, i.e. Cstat, DLCO, DM, VC, which seem to be more significant for early detection of functional disorders in sarcoidosis. Again the findings showed no significant differences neither between patients treated with prednisolone for 12 or 6 months respectively nor when compared to the untreated group. In conclusion we do not treat patients with asymptomatic intrathoracic sarcoidosis and without extrapulmonary manifestations before the disease shows no regressive course within one year or when a progressive course is observed.
一项评估皮质类固醇治疗胸内结节病价值的前瞻性临床试验的初步结果表明，数年后，治疗组和未治疗组患者在临床、放射学和功能结局方面并无差异。在172例患者中，经过更长的随访期（平均8.9年）后，我们通过相同测试以及额外的生理评估（即Cstat、DLCO、DM、VC）对之前的结果进行验证，这些生理评估似乎对结节病功能障碍的早期检测更为重要。研究结果再次表明，分别接受12个月或6个月泼尼松龙治疗的患者之间，以及与未治疗组相比，均无显著差异。总之，对于无症状的胸内结节病且无肺外表现的患者，在疾病一年内未显示退行性病程或观察到进行性病程之前，我们不进行治疗。
